Treatment Sequencing & Twice-Yearly Dosing [BACKUP]

Aggregator

03 Nov 2026 0 comments

Dr. Muley frames two use cases: (1) Early use (<1 year disease duration) to intercept long-lived plasma cell formation and potentially reduce steroid/immunosuppressant reliance; (2) Later use in patients who have failed steroids, conventional ISTs, or downstream therapies (FcRn inhibitors, complement inhibitors).